Drug Trial News

RSS

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition.

28 Nov 2012

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete.

28 Nov 2012

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

28 Nov 2012

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Elan Corporation, plc today announced that it has enrolled the first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to severe Alzheimer's disease (AD).

28 Nov 2012

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

Amarantus BioSciences, Inc., a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

27 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD).

26 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Synta Pharmaceuticals Corp. announced today that interim results of the Phase 2b portion of the GALAXY program will be presented on November 28, 2012 at 12:15 p.m. (JST) during the "Highlights of Oral Presentations" session at the Fifth Asia Pacific Lung Cancer Conference (APLCC 2012) in Fukuoka City, Japan.

26 Nov 2012

Cancer-killing viruses found safe but less effective than expected

Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.

26 Nov 2012

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).

26 Nov 2012

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Lymphopenia is when you lack the T cells of your immune system. T cells are very important for controlling infection. Probably the most known cause of lymphopenia is HIV.

23 Nov 2012

Allon Files Preliminary Shelf Prospectus

Allon Therapeutics Inc. has filed a preliminary short form base shelf prospectus with the securities commissions in each province and territory of Canada (other than Quebec).

23 Nov 2012

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.

22 Nov 2012

Bowel cancer and GIST patients could benefit from novel oral drug

Two phase 3 trials, published in The Lancet, have shown that a novel oral drug called regorafenib could offer survival benefits to people with bowel (colorectal) cancer or gastrointestinal stromal tumour (GIST) following failure of existing treatments.

22 Nov 2012

University of Liverpool to conduct immunoglobulin clinical study for complex regional pain syndrome

Scientists at the University of Liverpool are leading a -1.5 million project to study `immunoglobulin', a type of drug which has been shown to ease complex regional pain syndrome (CRPS).

22 Nov 2012

Somnogen induces sleep in patients with primary hypersomnia

Researchers at Emory University School of Medicine have discovered that dozens of adults with an elevated need for sleep have a substance in their cerebrospinal fluid that acts like a sleeping pill.

22 Nov 2012

Citicoline not superior to placebo in treating traumatic brain injury

Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.

22 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Drug Trial News

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Cancer-killing viruses found safe but less effective than expected

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Allon Files Preliminary Shelf Prospectus

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

Bowel cancer and GIST patients could benefit from novel oral drug

University of Liverpool to conduct immunoglobulin clinical study for complex regional pain syndrome

Somnogen induces sleep in patients with primary hypersomnia

Citicoline not superior to placebo in treating traumatic brain injury

Regorafenib able to control resistant gastrointestinal stromal tumor

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News